Skip to main content
Elizabeth Plimack, MD, Oncology, Philadelphia, PA

Elizabeth R. Plimack MD MS

Genitourinary Oncology


Chief, Division of Genitourinary Medical Oncology. Director, Genitourinary Clinical Research. Associate Professor, Department of Hematology/Oncology.

Join to View Full Profile
  • 333 Cottman AveFox Chase Cancer CenterPhiladelphia, PA 19111

  • Phone+1 215-728-6900

  • Fax+1 215-728-3639

Dr. Plimack is on Doximity

As a Doximity member you'll join over two million verified healthcare professionals in a private, secure network.

  • Gain access to free telehealth tools, such as our “call shielding” and one-way patient texting.
  • Connect with colleagues in the same hospital or clinic.
  • Read the latest clinical news, personalized to your specialty.

Education & Training

  • University of Texas Health Science Center at Houston/M D Anderson Cancer Center
    University of Texas Health Science Center at Houston/M D Anderson Cancer CenterFellowship, Hematology and Medical Oncology, 2005 - 2008
  • NYU Grossman School of Medicine
    NYU Grossman School of MedicineResidency, Internal Medicine, 2002 - 2005
  • New York University School of Medicine
    New York University School of MedicineClass of 2002

Certifications & Licensure

  • PA State Medical License
    PA State Medical License 2008 - 2026
  • TX State Medical License
    TX State Medical License 2005 - 2008
  • Medical Oncology
    American Board of Internal Medicine Medical Oncology

Awards, Honors, & Recognition

  • CMS Meaningful Use Stage 1 Certification EpicCare Ambulatory EMR, Epic Systems Corporation, 2013
  • Whos Who in Medicine and Healthcare Marquis Whos Who

Clinical Trials

Publications & Presentations

PubMed

Journal Articles

  • Pan-Tumor Genomic Biomarkers for PD-1 Checkpoint Blockade–Based Immunotherapy  
    Jonathan Cheng, Patrick A Ott, Elizabeth R Plimack, Antoni Ribas, Andrew Joe, Science Magazine

Press Mentions

  • Bladder Cancer Survival Better with Nivolumab Than Placebo in New Analysis
    Bladder Cancer Survival Better with Nivolumab Than Placebo in New AnalysisFebruary 21st, 2025
  • Adjuvant Nivolumab Boosts Survival Outcomes in Muscle-Invasive Bladder Cancer
    Adjuvant Nivolumab Boosts Survival Outcomes in Muscle-Invasive Bladder CancerFebruary 17th, 2025
  • ASCO GU 2023: Update on Bladder-Sparing Treatment Trial: RETAIN BLADDER
    ASCO GU 2023: Update on Bladder-Sparing Treatment Trial: RETAIN BLADDERFebruary 15th, 2023
  • Join now to see all

Professional Memberships

Viewing the full profile is available to verified healthcare professionals only.

Find your profile and take control of your online presence: